-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Various -X- _ O
pathways -X- _ O
have -X- _ O
been -X- _ O
implicated -X- _ O
in -X- _ O
the -X- _ O
pathogenesis -X- _ O
of -X- _ O
heart -X- _ O
failure -X- _ O
( -X- _ O
HF -X- _ O
) -X- _ O
with -X- _ O
preserved -X- _ O
ejection -X- _ O
fraction -X- _ O
( -X- _ O
HFPEF -X- _ O
) -X- _ O
. -X- _ O
Inflammation -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
comorbid -X- _ O
conditions -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
hypertension -X- _ O
and -X- _ O
diabetes -X- _ O
, -X- _ O
may -X- _ O
play -X- _ O
a -X- _ O
proportionally -X- _ O
larger -X- _ O
role -X- _ O
in -X- _ O
HFPEF -X- _ O
as -X- _ O
compared -X- _ O
to -X- _ O
HF -X- _ O
with -X- _ O
reduced -X- _ O
ejection -X- _ O
fraction -X- _ O
( -X- _ O
HFREF -X- _ O
) -X- _ O
. -X- _ O
METHODS -X- _ O
AND -X- _ O
RESULTS -X- _ O
: -X- _ O
This -X- _ O
study -X- _ O
investigated -X- _ O
inflammation -X- _ O
mediated -X- _ O
by -X- _ O
the -X- _ O
tumor -X- _ B-Intervention
necrosis -X- _ I-Intervention
factor-alpha -X- _ I-Intervention
( -X- _ I-Intervention
TNFα -X- _ I-Intervention
) -X- _ I-Intervention
axis -X- _ I-Intervention
in -X- _ O
community-based -X- _ O
cohorts -X- _ O
of -X- _ O
HFPEF -X- _ B-Patient
patients -X- _ I-Patient
( -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
100 -X- _ I-Patient
) -X- _ I-Patient
, -X- _ I-Patient
HFREF -X- _ I-Patient
patients -X- _ I-Patient
( -X- _ I-Patient
n -X- _ I-Patient
= -X- _ I-Patient
100 -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
healthy -X- _ B-Comparison
controls -X- _ I-Comparison
( -X- _ I-Comparison
n -X- _ I-Comparison
= -X- _ I-Comparison
50 -X- _ I-Comparison
) -X- _ I-Comparison
. -X- _ O
Enzyme-linked -X- _ O
immunosorbent -X- _ O
assays -X- _ O
were -X- _ O
used -X- _ O
to -X- _ O
investigate -X- _ O
levels -X- _ O
of -X- _ O
TNFα -X- _ O
, -X- _ O
its -X- _ O
two -X- _ O
receptors -X- _ O
( -X- _ O
TNFR1 -X- _ O
and -X- _ O
TNFR2 -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
non-TNFα -X- _ O
cytokine -X- _ O
, -X- _ O
interleukin-6 -X- _ O
( -X- _ O
IL-6 -X- _ O
) -X- _ O
, -X- _ O
in -X- _ O
plasma -X- _ O
derived -X- _ O
from -X- _ O
peripheral -X- _ O
blood -X- _ O
samples. -X- _ O
Plasma -X- _ B-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
TNFα -X- _ I-Outcome
and -X- _ I-Outcome
TNFR1 -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
elevated -X- _ I-Outcome
in -X- _ I-Outcome
HFPEF -X- _ I-Outcome
relative -X- _ I-Outcome
to -X- _ I-Outcome
controls -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
TNFR2 -X- _ I-Outcome
were -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
HFPEF -X- _ I-Outcome
than -X- _ I-Outcome
both -X- _ I-Outcome
controls -X- _ I-Outcome
and -X- _ I-Outcome
HFREF. -X- _ I-Outcome
TNFα -X- _ I-Outcome
, -X- _ I-Outcome
TNFR1 -X- _ I-Outcome
and -X- _ I-Outcome
TNFR2 -X- _ I-Outcome
were -X- _ I-Outcome
each -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
two -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
following -X- _ I-Outcome
: -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
estimated -X- _ I-Outcome
glomerular -X- _ I-Outcome
filtration -X- _ I-Outcome
rate -X- _ I-Outcome
, -X- _ I-Outcome
hypertension -X- _ I-Outcome
, -X- _ I-Outcome
diabetes -X- _ I-Outcome
, -X- _ I-Outcome
smoking -X- _ I-Outcome
, -X- _ I-Outcome
peripheral -X- _ I-Outcome
vascular -X- _ I-Outcome
disease -X- _ I-Outcome
or -X- _ I-Outcome
history -X- _ I-Outcome
of -X- _ I-Outcome
atrial -X- _ I-Outcome
fibrillation. -X- _ I-Outcome
TNFR2 -X- _ I-Outcome
levels -X- _ I-Outcome
were -X- _ I-Outcome
also -X- _ I-Outcome
significantly -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
increasing -X- _ I-Outcome
grade -X- _ I-Outcome
of -X- _ I-Outcome
diastolic -X- _ I-Outcome
dysfunction -X- _ I-Outcome
and -X- _ I-Outcome
severity -X- _ I-Outcome
of -X- _ I-Outcome
symptoms -X- _ I-Outcome
in -X- _ I-Outcome
HFPEF. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Inflammation -X- _ O
mediated -X- _ O
through -X- _ O
TNFα -X- _ O
and -X- _ O
its -X- _ O
receptors -X- _ O
, -X- _ O
TNFR1 -X- _ O
and -X- _ O
TNFR2 -X- _ O
, -X- _ O
may -X- _ O
represent -X- _ O
an -X- _ O
important -X- _ O
component -X- _ O
of -X- _ O
a -X- _ O
comorbidity-induced -X- _ O
inflammatory -X- _ O
response -X- _ O
that -X- _ O
partially -X- _ O
drives -X- _ O
the -X- _ O
pathophysiology -X- _ O
of -X- _ O
HFPEF -X- _ O
. -X- _ O

